title: PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.
abstract: Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha(®)), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.
authors.affiliation: MedStar Franklin Square Medical Center, Department of Medicine, Baltimore, MD, USA.
authors.forename: Chanukya
authors.initials: C
authors.lastname: Dahagam
authors.affiliation: MedStar Franklin Square Medical Center, Department of Medicine, Baltimore, MD, USA.
authors.forename: Aditya
authors.initials: A
authors.lastname: Goud
authors.affiliation: MedStar Franklin Square Medical Center, Department of Medicine, Baltimore, MD, USA.
authors.forename: Abdelhai
authors.initials: A
authors.lastname: Abdelqader
authors.affiliation: MedStar Good Samaritan/Union Memorial Hospital, Department of Medicine, Baltimore, MD, USA.
authors.forename: Aditya
authors.initials: A
authors.lastname: Hendrani
authors.affiliation: Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Feinstein
authors.affiliation: Cardiovascular Division, Brigham & Womens Hospital, Boston, MA, USA.
authors.forename: Arman
authors.initials: A
authors.lastname: Qamar
authors.affiliation: Cardiovascular Division, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Parag H
authors.initials: PH
authors.lastname: Joshi
authors.affiliation: Cardiovascular Division, Vanderbilt University Medical Center, Nashville, TN, USA.
authors.forename: Kristopher J
authors.initials: KJ
authors.lastname: Swiger
authors.affiliation: Pediatric Cardiology, Johns Hopkins Hospital, Baltimore, MD, USA.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Byrne
authors.affiliation: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Carnegie 591, Baltimore, MD 21287, USA.
authors.forename: Renato
authors.initials: R
authors.lastname: Quispe
authors.affiliation: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Carnegie 591, Baltimore, MD 21287, USA.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Jones
authors.affiliation: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Carnegie 591, Baltimore, MD 21287, USA.
authors.forename: Roger S
authors.initials: RS
authors.lastname: Blumenthal
authors.affiliation: Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Carnegie 591, Baltimore, MD 21287, USA.
authors.forename: Seth S
authors.initials: SS
authors.lastname: Martin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL / Q000097:blood*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000091362:PCSK9 Inhibitors; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; C577155:evolocumab
keywords: LDL; PCSK9 inhibitors; alirocumab; evolocumab; monoclonal antibodies; statin intolerance